Abvc Biopharma (ABVC) Work In Process (2018 - 2019)
Abvc Biopharma's (ABVC) quarterly Work In Process came in at $20676.0 in Q4 2019, up 2.14% YoY from $20243.0 in Q4 2018, and up 3.71% on a QoQ basis from $19937.0 in Q3 2019.
Abvc Biopharma (ABVC) Work In Process (2018 - 2019) Analysis & Trends
Abvc Biopharma (ABVC) has 2 years of Work In Process data on file, last reported at $20676.0 in Q4 2019.
- Quarterly Work In Process rose 2.14% year-over-year to $20676.0 in Q4 2019, while the trailing twelve-month figure through Dec 2019 was $20676.0 (up 2.14% YoY) and the FY2019 annual result came in at $20676.0, up 2.14% from the prior year.
- Work In Process advanced to $20676.0 in Q4 2019, from $19937.0 in the prior quarter.
- In the past five years, Work In Process ranged from a high of $20676.0 in Q4 2019 to a low of $19933.0 in Q2 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.82 Bn | 131.97 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.27 Bn | 60.09 Bn | 1.37 Bn |
| 4 | Moderna | 59.18 Bn | 54.04 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.11 Bn | 37.01 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.80 Bn | 28.49 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.14 Bn | 9.75 Bn | 668.28 Mn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.26 Bn | 26.42 Bn | - |
| 10 | Abvc Biopharma | 24.23 Mn | 24.23 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | 20,676.00 |
| Sep 30, 2019 | 19,937.00 |
| Jun 30, 2019 | 19,933.00 |
| Mar 31, 2019 | 20,057.00 |
| Dec 31, 2018 | 20,243.00 |